	US 11,787,849 B2
	Methods and compounds for eliminating immune responses to therapeutic agents
Jean-Marie Saint-Remy, Grez-Doiceau (BE); Luc Vander Elst, Obaix (BE); and Vincent Carlier, Enimes (BE)
Assigned to IMCYSE SA, Liège (BE)
Appl. No. 15/761,223
Filed by IMCYSE SA, Liège (BE)
PCT Filed Sep. 23, 2016, PCT No. PCT/EP2016/072690 § 371(c)(1), (2) Date Mar. 19, 2018, PCT Pub. No. WO2017/050966, PCT Pub. Date Mar. 30, 2017.
Claims priority of application No. 15186845 (EP), filed on Sep. 25, 2015.
Prior Publication US 2018/0258154 A1, Sep. 13, 2018
Int. Cl. A61K 35/12 (2015.01); A61K 8/60 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 38/19 (2006.01); A61K 38/22 (2006.01); A61K 38/36 (2006.01); A61K 39/00 (2006.01); C12N 9/02 (2006.01); C07K 14/74 (2006.01); A61K 39/39 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01)

CPC C07K 14/70539 (2013.01) [A61K 39/001 (2013.01); A61K 39/39 (2013.01); C12N 9/0004 (2013.01); A61K 38/00 (2013.01); A61K 2035/122 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/572 (2013.01); A61K 2039/627 (2013.01); A61K 2039/70 (2013.01); C07K 2319/40 (2013.01)]

12 Claims

1. A kit of parts of polypeptides comprising:

a) a peptide comprising:

a1) a first peptide sequence comprising an MHC class II T cell epitope, and

a2) immediately adjacent to said first peptide sequence or separated by at most 7 amino acids from said first peptide sequence a [CST]-X(2)-C [SEQ ID NO:7] or C-X(2)-[CST] [SEQ ID NO:8] oxidoreductase motif sequence, and

b) a fusion polypeptide comprising as fusion partners:

b1) a therapeutic protein and

b2) the first peptide sequence defined in al), wherein the first peptide sequence does not occur in the sequence of the protein of b1).